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Targeted cancer therapiesInhibitors of poly(ADP-ribose) polymerases actualized the biological concept of synthetic lethality in the clinical
practice, yielding a paradigmatic example of translational medicine. The profound sensitivity of tumors with
germline BRCA mutations to PARP1/2 blockade owes to inherent defects of the BRCA-dependent homologous
recombination machinery, which are unleashed by interruption of PARP DNA repair activity and lead to DNA
damage overload and cell death. Conversely, aspirant BRCA-like tumors harboring somatic DNA repair dysfunctions
(a vast entity of genetic and epigenetic defects known as “BRCAness”) not always align with the familial counter-
part and appear not to be equally sensitive to PARP inhibition. The acquisition of secondary resistance in initially
responsive patients and the lack of standardized biomarkers to identify “BRCAness” pose serious threats to the
clinical advance of PARP inhibitors; a feeling is also emerging that a BRCA-centered perspectivemight havemissed
the inﬂuence of additional, not negligible and DNA repair-independent PARP contributions onto therapy outcome.
While regulatory approval for PARP1/2 inhibitors is still pending, novel therapeutic opportunities are sprouting
from different branches of the PARP family, although they remain immature for clinical extrapolation. This review
is an endeavor to provide a comprehensive appraisal of themultifaceted biology of PARPs and their evolving impact
on cancer therapeutics.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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When the poly(ADP-ribose) polymerase (PARP) superfamily was
discovered, back in the early 1960s [1], it was hardly predictable that
abundant and rather elementary molecules, namely poly(ADP)ribose
(PAR) units, would drastically impact upcoming scientiﬁc research.
The PARP superfamily encompasses at least 17 enzymes involved in
several biological processes, including transcriptional regulation, DNA re-
pair, cell cycle regulation, inﬂammation, hypoxic response, spindle pole
function, oncogene-related signaling, and cell death [2–4]. As some
PARP familymembers catalyzemono- rather than poly(ADP)ribosylation,
a more accurate nomenclature has been recently proposed that renames
PARPs as ADP-ribosyltransferases diphtheria toxin-like (ARTD) [5]. PARP1
(ARTD1) is the foundingmember as well as themost abundant and best-
characterized protein within this large family. Although historically
reviewed as a DNA repair enzyme [6], PARP1 is being increasingly impli-
cated in cell homeostasis at several levels, including transcriptional and
epigenetic mechanisms [3]. PARP1's closest relative, PARP2 (ARTD2),
displays almost overlapping functions [7]. Outside the archetypal
PARP1 and PARP2, latest reports have implicated PARP3 (ARTD3) in
DNA repair, mitotic spindle integrity, and telomerase regulation [8,9].
PARP4 (ARTD4) is part of a cytoplasmic ribo-nucleoprotein structure,
known as the vault complex, whose function is uncertain, although it
has been related to multidrug resistance in some cell lines [2]. PARP5A
(ARTD5) and PARP5B (ARTD6), also referred to as tankyrase 1 (TNKS)
and tankyrase 2 (TNKS2), stand out as founders of an alternative branch
of the PARP summa, involving telomere andmitotic spindle-related func-
tions, as well as regulation of theWnt signaling. Consequently, this latter
line of investigation is now being inﬂated with high clinical expectations
[10]. Other PARPs have been less extensively studied, with initial infor-
mation attesting to their potential role as effectors in cell division, cell
viability, and transduction of cytoskeletal cues [10,11].
Historically, PARP couples with BRCA. Germline inactivation of
BRCA1/2 tumor suppressor genes strongly predisposes to breast and
ovarian cancer as well as other malignancies, including pancreatic and
prostate cancer [12,13]. Tumor suppressors are hardly accessible to
pharmacologic interception; however, the concept of synthetic lethality
(broadly referred to as non-oncogene addiction) has outlined an
intriguing avenue for targeting tumor suppressor defects [14]. Two
genes are synthetically lethal if depletion of either alone is viable
whereas concurrent loss results in cell death [15]. This notion has
been epitomized and successfully extrapolated to the clinical practice
by PARP inhibitors, which are effective in BRCA-related tumors due
to sabotage of functionally interdependent DNA repair routes that
ultimately leads to cellular toxicity [16].
It is expected that a broader spectrumof tumors, displaying inherent
or acquired DNA repair dysfunction regardless of the leading genetic
lesion, exhibit a BRCA-like behavior and beneﬁt from PARP-targeted
strategies [17]. After almost one decade of eager investigation and
high expectations, enthusiasm has been tempered by disappointing
trial outcomes, wherein “BRCAness” could not obviously predict
favorable responses [18]. Therefore, upgrading PARP inhibitorsbeyond experimental use seems to be facing many roadblocks. Lagging
behind, new drug development efforts are chasing additional members
of the PARP superfamily, namely tankyrases, which may hold a clinical
value as integral components of several cancer-related pathways [10].
In this review, we focus on fortune and downfalls of PARP-directed
approaches and underscore emerging lines of investigation, including
and beyond the archetypal PARP-DNA repair duo. Table 1 summarizes
recently completed and ongoing trials with ﬁrst- and last-generation
PARP inhibitors, on which we will touch in the following sections.
2. Rationale for PARP-targeted therapeutics
2.1. DNA repair mechanisms
A complex network of molecular players is allocated for preserving
genomic integrity from a myriad of endogenous and environmental
insults. DNA single-strand breaks (SSBs) are repaired by the base-
excision repair (BER), the nucleotide-excision repair (NER) or
the mismatch repair (MMR) pathways, whereas double-strand
breaks (DSBs) engage either homologous recombination (HR) or
non-homologous end joining (NJEJ) [19]. The BER machinery recognizes
single-base lesions resulting from oxidation, alkylation and deamination;
it involves a large number of enzymes, including DNA glycosylases, APE1,
ERCC1, DNA polymerase beta, DNA ligase 3, and PARP1 itself [20]. NER is
activated by helix-distorting lesions and is the main pathway for the
repair of UV-induced DNA alterations [19]. MMR removes replication
errors, i.e. mismatched nucleotides and little insertion/deletion loops.
Defects in this pathway result in highmutation rate and cancer, including
hereditary non-polyposis colorectal cancer [19].
DSBs are more threatening, because the complementary strand
is not always available for faithful repair. The HR pathway is operative
exclusively in the S andG2phases of the cell cycle,where the accessibility
of a homologue template, usually a sister chromatid, ensures accurate
DNA repair. It starts with binding of the MNR complex (MRE11/RAD50/
NBS1) to DSBs, followed by recruitment of CtIP and activation of
MRE11-mediated DSB resection [21]. The resultant ssDNA is then
bound by RAD51, a very critical step which ultimately leads to
template-dependent DNA synthesis. BRCA1 and BRCA2 play a role in
RAD51 loading, together with other HR components, such as ATM,
H2AX, PALB2, RPA, RAD52, and proteins of the Fanconi anemia pathway
[22]. Unlike HR, NHEJ is operative throughout the cell cycle andmediates
direct ligation of broken DNA ends without requiring a template DNA
[23]; therefore, it is highly mutagenic
2.2. PARP1 in DNA damage repair
Huge efforts have been devoted to elucidate the role of PARP1 and
PARP2 in DNA repair [24], with higher emphasis on PARP1 as it accounts
for the vast majority of PAR synthesis [25]. It is well-established that,
following DNA damage, PARP1 senses and binds to DNA strand inter-
ruptions, whereby it becomes catalytically activated. Using NAD+ as a
substrate, PARP1 catalyzes the attachment of PAR polymers onto
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PARP1 itself [3]. Besides relaxing chromatin structure, this post-
translational modiﬁcation results in reduced afﬁnity and consequent
PARP1 dissociation from DNA, allowing for access to an orchestrated
network of repair enzymes [26,27]. Although PARP1 has long been an-
notated as a BER effector by assisting the assembly of a core-complex
comprising XRCC1, Polβ, and DNA ligase III [27,28], recent data propose
an indirect mechanism, according to which PARP1 activity would be
dispensable for BER sheer execution, and would be rather engaged to
seize potentially detrimental SSB intermediates and to promote their
resolution [29]. Recently, PARP1 contribution to SSB repair has also
been extended to MMR and NER [30,31]. Besides its canonical role in
sensing SSBs, PARP1 was reported to bind to and assist the repair of ad-
ditional damaged DNA structures, including stalled replication forks
and DSBs, inﬂuencing both HR and NHEJ [32–34].Table 1
Overview of completed and ongoing clinical trials with PARP inhibitors.www.clinicaltrials.gov.
Drug a Phase Intervention Cancer type
Olaparib Phase Ia Combination Ovarian, breast, esophagus, lung, brain, uterin, hea
fallopian, endometrial, cervical, peritoneal, colorec
other unspeciﬁed solid tumors
Combination Breast, ovarian, peritoneal, fallopian, other unspec
Monotherapy Unspeciﬁed solid tumors
Monotherapy Ovarian
Phase II Combination Breast, ovarian, fallopian, peritoneal, prostate
Combination Gastric, pancreatic
Lung
Monotherapy Prostate, Ewing's sarcoma, ovarian
Monotherapy Ovarian, breast, prostate, pancreatic, peritoneal, fa
other unspeciﬁed solid
Phase III Combination Gastric
Monotherapy Colorectal cancer
Breast, ovarian
Veliparib Phase I Combination Peritoneal, fallopian, ovarian, pancreatic, lymphom
liver, rectal, breast, melanoma, colorectal, gastric p
other unspeciﬁed solid tumors
Combination Breast, ovarian, other unspeciﬁed solid tumors
Monotherapy Gastric, ovarian, breast, fallopian, peritoneal, leuke
other unspeciﬁed solid tumors
Monotherapy Breast, ovarian, other unspeciﬁed solid tumors
Phase II Combination Lung, ovarian, fallopian, peritoneal, breast, head a
pancreatic, liver, colorectal, brain, melanoma othe
Combination Pancreatic, breast, ovarian
Ovarian
Monotherapy Pancreatic, breast, ovarian
Monotherapy Breast, fallopian, ovarian, peritoneal
Phase III Combination Breast
Rucaparib Phase I Combination Unspeciﬁed solid tumors
Monotherapy Ovarian, fallopian, peritoneal
Phase II Combination Breast
Monotherapy Ovarian, fallopian, peritoneal
Monotherapy Breast, ovarian, pancreatic
Phase III Monotherapy Ovarian, fallopian, peritoneal
BMN-673 Phase I Combination Unspeciﬁed solid tumors
Monotherapy Leukemia, lymphoma, myelodisplastic syndrome
Monotherapy Breast, ovarian, lung, prostate, pancreatic, Ewing's
Phase II Monotherapy Ovarian, breast, peritoneal, other unspeciﬁed solid
Phase III Monotherapy Breast
Niraparib Phase I Combination Ovarian, brain, melanoma, other unspeciﬁed solid
Monotherapy Leukemia, unspeciﬁed solid tumors
Phase III Monotherapy Breast, ovarian
Breast
CEP9722 Phase I Combination Lymphoma, unspeciﬁed solid tumors
Monotherapy Unspeciﬁed solid tumors
Phase II Monotherapy Unspeciﬁed solid tumors
E7016 Phase I Combination Unspeciﬁed solid tumors
Phase II Combination Melanoma
AZD-2461 Phase I Monotherapy Unspeciﬁed solid tumors
INO-1001 Phase I Combination Melanoma
E7449 Phase I/II Combination Melanoma, breast
Monotherapy Ovarian, B-cell malignancies
a Iniparib is not included in the table due to its poor selectivity toward PARPs.Overall, these ﬁndings emphasize the complexity of PARP-related
DNA repair routes and rationalize the relevance of this enzyme in the
safeguard of genome stability.
2.3. BRCA1/2 in DNA repair
BRCA1 is involved in multiple steps of HR-directed DNA repair. It
binds to and enters phosphorylated CtIP into the damaged site, resulting
inMRE11-mediated resection [35]. Moreover, it interacts with PALB2 to
engage the BRCA1–PALB2–BRCA2 complex [36]. Then, BRCA2 directly
binds and recruits RAD51 onto the ssDNA resected end, which is
propaedeutic for the ensuing recombination events [37]. Besides coordi-
nating HR execution, BRCA1 plays a role in both the G1/S and G2/M cell
cycle checkpoint regulation in response toDNAdamage, again preserving
genomic integrity [38]. In keeping with these notions, germlinePatient stratiﬁcation
d and neck Ewing's sarcoma,
tal, melanoma, pancreatic,
No
iﬁed solid tumors BRCA mut
No
BRCA mut
No
ATM loss, BRCA/FA pathway mut
EGFR mut
No
llopian, BRCA mut
No
MSI status
BRCA mut
a, leukemia, lung, bladder,
rostate, brain,
No
BRCA/FA pathway mut
mia, lymphoma No
BRCA/FA pathway mut, BRCA1 promoter methylation
nd neck, cervical, prostate,
r unspeciﬁed solid tumors
No
BRCA/PALB2 mut
non-BRCA
No
BRCA mut
BRCA mut
No
No
BRCA mut
No
BRCA mut
BRCA mut, other HR gene alteration
No
No
sarcoma BRCA mut
tumors BRCA mut
BRCA mut
tumors No
No
BRCA mut
BRCA mut, non-HER2
No
No
BRCA mut, other HR gene alteration
No
wt BRAF
No
No
No
ATM mut
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the lifetime risk of developing breast, ovarian, prostate, and pancreas
cancers [13].
2.4. Supporting notions for targeting PARPs as anticancer strategy
Two conceptually unrelated anticancer strategies vindicate the use
of PARP inhibitors as either single agents or in combinationwith chemo-
therapy or radiotherapy. The rationale for combination therapies is
obviously linked to PARP1 as an integral element of the DNA damage
response (DDR), which cancer cells rewire to resist DNA-damaging
drugs [39]. Unfortunately, DDR is poorly compliant to pharmacologic
obstruction; several DDR inhibitors are currently tested in the clinic,
but they generally display unfavorable toxicity proﬁles [40]. Since
PARP1 impacts many of DDR circuits, PARP inhibitors are expected to
overwhelm DDR and kill cancer cells [41].
The most intriguing application of PARP inhibitors is monothera-
py in HR-defective cancers, a molecular setting in which synthetic le-
thality is exploited. This notion has unlocked the therapeutic
potential to selectively kill cancer cells by capitalizing on their inher-
ent vulnerabilities including genomic instability, a well-known hall-
mark of cancer [42,43]. Faulty genome surveillance delivers a
double-edged outcome: while facilitating the acquisition of tumor-
promoting lesions, it needs to be buffered by compensatory routes
to escape DNA damage overload and cell death. The ensuing reliance
on these offsetting pathways can be therapeutically harnessed to
drive toxicity [40,44]. This is particularly pertinent to hereditary
BRCA1/2 mutated cancers, in which ineffective HR-driven DNA re-
pair offers a permissive milieu for overriding cell tolerance to DNA
damage [45,46]. In the BRCA-mutation setting, as well as in any ge-
netic background resulting in HR dysfunction, PARP blockade causes
replication-associated lesions that cannot be repaired by inherently
defective HR, thereby encouraging the activation of compensatory,
error-prone DNA repair pathways. This leads to genomic instability,
non-viable genetic errors and, eventually, cell death [17,47].
2.5. Proposed mechanisms for PARP-BRCA synthetic lethality
The exact molecular mechanism underlying the selective killing of
HR-deﬁcient cells by PARP inhibition is yet incompletely understood
and is a matter of intense debate. An accepted explanation is based on
the assumption that PARP1-inhibited cells accumulate unrepairedSSB
SSB
repair
Repaired DNA
Replication
Trapped PARP
Col
OneUnrepaired SSB
PARP 
inhibitor 
Fork
A
B
Fig. 1.Molecular pathways underlying PARP/BRCA synthetic lethality. Red dotted lines indicate pro
SSB repair is precluded and either PARP is trapped onto DNA (A) or unrepaired SSBs are con
replication fork damage requires operational HR for efﬁcient restart (C). HR-deﬁcient BRCAmut
instability and cell death.SSBs, which are eventually converted to DSBs when encountered by
the replication machinery; in the absence of BRCA1/2, HR repair is dis-
abled and cells reroute to alternative low-ﬁdelity DNA repair pathways,
thus hastening genomic instability and cell death [47] (Fig. 1). PARP1
per se has a controlling role in NHEJ [34], supporting a model whereby
contextual deﬁciency of PARP1 and BRCA would lead to a shift toward
NHEJ, resulting in synthetic lethality [48]. Another proposed theory is
that PARP1 and HR-related proteins mediate distinct pathways for the
restart of stalled replication forks; therefore, PARP inhibition would be
selectively toxic in HR-defective cells [49].
A conceptually different interpretation recalls the notion that
auto-ADP ribosylation is necessary for PARP1 dissociation from
DNA. Hence, the so called “PARP1-trapping model” has been theorized
suggesting that PARP inhibitors capture PARP1 onto DNA repair inter-
mediates [29]; these PARP-DNA aggregates are likely to impede DNA
replication and require functional HR for efﬁcient restart [49]. This anal-
ysis has been recently integrated byMurai et al., whodemonstrated that
trapped PARP-DNA is per se a more toxic lesion than unrepaired SSBs.
These PARP-DNA structures necessitate efﬁcient HR for resolution,
thus explaining the synthetic lethal effect [50]. Consistent with PARP
inhibitors being cellular poisons rather than catalytic inhibitors, the
extent of PARP trapping by different inhibitors positively correlates
with cytotoxicity [51].
Overall, despite the fragmented nature of these data, there is no
evidence of mutual exclusion. A coherent picture would posit that
PARP inhibitionmay generate asmany lesions as the range of individual
DNA repair nodes affected, including stalled replication forks, DSBs and
trapped intermediates, all of which are substrates for HR. In the absence
of functional HR, unwarranted activation of low-ﬁdelity NHEJ drives
accumulation of non-viable errors and selective toxicity.
2.6. BRCAness and BRCA-like tumors: broadening therapeutic routes
The concept of “BRCAness” was ﬁrst established by Ashworth in
2004 to include clinical and biological features that some sporadic
tumors share with those harboring germline BRCA mutations [52]. The
ﬁnding that depletion of HR repair components other than BRCA1/2
(i.e. the MRN complex, PALB2, RAD51, RAD54, DSS1, RPA1, NBS1, ATR,
ATM, CHK1, CHK2, FANCD2, FANCA, and FANCC) is synthetic lethal
with PARP inhibition provides proof of concept that HR deﬁciency,
regardless of the underlying genetic lesion, can be therapeutically
exploited to expand the pool of patients entitled to PARP-targetedlapsed fork
-sided DSB
HR repair
(BRCA)
Genomic stability
NHEJ 
Cell survival
(HR competence)
Genomic instability
Cell death
(HR dysfunction)
Replication restart damage
Non-viable errors
D
C
cesses impaired by PARP blockade inHR-defective cells. In the presence of PARP inhibitors,
verted to DSBs by collision with the replication machinery (B). In both cases, resultant
ant cells redirect to alternative, error-proneDNA repair pathways (D), undergoing genomic
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inhibitors are very toxic in ATM-deﬁcient cancer cells [54] and
prove also effective in a variety of other BRCA-unrelated HRR deﬁ-
cient tumors, including microsatellite unstable colorectal cancers with
MRE11 mutations [55] and RAD51C-deﬁcient cancer cells [56].
ATM, MRE11 and RAD51, as well as other HR repair genes, are
actually disrupted by genetic or epigenetic mechanisms in a signiﬁcant
proportion of sporadic tumors [53] (Fig. 2). This outlines the rationale
for molecular proﬁling of non-BRCA genes to guide patient enrollment
into clinical trials. PARP inhibitors are already used in phase I/II
studies involving/enriched in ATM-deﬁcient tumors (NCT01618136;
NCT01063517), and many other synthetic lethal interactions are likely
to enter inclusion criteria in prospective clinical trials.
Functional dependencies might also involve HR-unrelated proteins
that yet provide ancillary paths to “BRCAness”. The mitotic serine/
threonine kinaseAurora A is frequently ampliﬁed in cancer. In preclinical
models, overexpression of Aurora A impairs RAD51 recruitment, thus
disabling DSB repair and sensitizing cells to PARP inhibition [57].
Recently, much interest has been focused on PTEN loss as amajor deter-
minant of BRCA-like features and sensitivity to PARP inhibitors andDNA
damaging agents, including a case report in a patient [58–61] (Fig. 2).
This issue remains in fact controversial: Shen et al. reported that PTEN
depletion impairs HR-driven repair by decreasing the expression of
RAD51 [62], butmore recent data indicate that this is unlikely to be a gen-
eral mechanism [63–65]. It is also confounding that, although PTEN-null
status is reported topositively identify PARP inhibitor responsiveness, yet
experimental PTEN down-regulation does not score positive in unbiased
RNA interference drug sensitization screens to PARP inhibitors [66].
More compelling evidence associates BRCAness to non-germline
BRCA status (Fig. 2). Somatic mutations of BRCA1/2 are rare in sporadic
cancers, but inactivation of these genes may occur via disparate mecha-
nisms. This is particularly relevant to breast and ovarian cancer. Triple
negative breast cancer (TNBC), mostly classiﬁed as basal-like (BL) by
gene expression analysis, shares common clinical and pathologic traits
with familial BRCA1-mutated breast cancers, including high frequency
of P53 mutation, aneuploidy, high pathologic grade, and relative
sensitivity to DNA-damaging chemotherapeutics [67,68]. Reportedly,
the molecular mechanisms underlying this similarity include transcrip-
tional down-regulation or (more frequently) epigenetic silencing of
BRCA1 [69–72]. Unlike BRCA1, BRCA2 functional inactivation is less
clear. BRCA2 promoter is rarely hyper-methylated in breast cancer,
but BRCA2 transcriptional down-regulation is frequently associated to
ampliﬁcation of the EMSY gene, occurring in up to 13% of sporadic,
mostly hormone-positive breast cancers [73] (Fig. 2). EMSY binds toSomatic mutations
Promoter hyper-
metilation (BRCA1)
EMSY 
amplification
Fanconi Anemia
Pathway inactivation
PTEN loss MRE11 mutations
ATM/ATR mutations
RAD51C hyper-methylation
HR dysfunction
PARP in
BRCA1/2 inactivation
- Biomarkers of
- Array-based p
Identify BRCA
AURORA A overexpression
Fig. 2. BRCA-like behavior in sporadic tumors. BRCAness may arise from genetic and epigenetic le
DNA repair in sporadic cancer. PARP blockade in this setting is expected to drive selective to
or array-based procedures can potentially widen the therapeutic span of PARP-targeted sand disables a transcriptional activation domain on BRCA2 exon 3
[74]; however, whether EMSY ampliﬁcation contributes to BRCAness
is still debated [53].
Ovarian cancer is a promising BRCA-like tumor as well. Molecular
proﬁling analysis reported HR dysfunction in up to 50% of high-grade-
serous ovarian cancers (HGSOC) [75]. A number of mechanisms are
thought to account for this phenotype, including BRCA1/2 somatic
mutations, hypermethylation of the BRCA1 promoter, EMSY ampliﬁca-
tion, inactivation of the Fanconi anemia pathway, epigenetic silencing
of RAD51C, and mutations of several other HR repair components and
related proteins, including ATM, ATR, BARD1, BRIP1, MRE11A, PALB2,
RAD50, RAD51D [76,77].
3. PARP blockade in cancer therapy
3.1. PARP inhibitors as chemo-/radio-potentiating agents
As early as in 1980, Durkacz and colleagues used the still immature,
low-potency PARP inhibitor 3-aminobenzamide (3-AB) to derail DNA
damage repair and enhance the cytotoxicity of dimethyl sulfate, a DNA
alkylating agent [78]. Since then, a huge number of preclinical studies
legitimated PARP inhibitors as sensitizing agents to DNA-damaging
drugs and radiotherapy [79–82]. The ﬁrst clinical trial in patients was
initiated in 2003 and allowed safety, pharmacokinetic and pharmacody-
namic evaluation of the PARP inhibitor AG014699 (rucaparib, displaying
a halfmaximal inhibitory concentration [IC50] of 1.4 nMby in vitro assays
with puriﬁed PARP1 [83]) in combination with temozolomide in
advanced solid tumors [84]. However, the subsequent phase II study in
melanoma [85], as well as additional independent clinical trials, featured
a common (albeit not universal) shortcoming of combinatorial strategies
with PARP inhibitors, namely, enhanced toxicity. Myelotoxicity was the
main dose-limiting concern, in the face of variable response rates
[86–89]. The need to reduce the dosage of either chemotherapy or
PARP inhibitor (or both) to overcome excessive toxicity raises obvious
questions about the real contribution of PARP inactivation to combinato-
rial regimens. Therefore, in spite of relentless efforts, still no deﬁnitive
conclusions can be drawn as to which combination regimen would
enhance the therapeutic index as compared with chemotherapy alone.
3.2. PARP inhibitors as single agents in tumors with germline HR deﬁciency
In 2005, two landmark studies fueled momentum to PARP-targeted
strategies by providing evidence that PARP1 inactivation is synthetic
lethal with BRCA1/2 deﬁciency, both in vitro and in vivo [90,91]. Furtherhibition
Cell deathDNA damage overload
 HR disruption
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-like tumors
sions (left panels) that phenocopy germline BRCA−/− background and disable HR-directed
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“BRCAness” context of HR dysfunction driven by genetic alterations
other than BRCA1/2 (see 3.3), envisaging an expanded therapeutic
window for prospective clinical applications [17].
The very ﬁrst evidence of clinical beneﬁt with a PARP inhibitor as
single agent was provided in 2009 by Fong and colleagues [92], who
conducted a dose-escalation study of olaparib (a potent PARP inhibitor
with in vitro IC50 values of 5 nMand 1 nMagainst PARP1 and PARP2, re-
spectively, and higher than 1 μMagainst TNKS [93]) in patients with ad-
vanced breast, lung, prostate, and ovarian cancer, registering striking
objective responses exclusively in the germline BRCA1/2 mutation
setting, withmanageable side effects [92]. These resultswere conﬁrmed
in an expansion cohort of BRCA-mutated ovarian cancer patients [94]
and in paired phase II clinical trials, which outlined encouraging dose-
dependent response rates of 33% and 41% in BRCA-mutant ovarian
and breast cancer, respectively [95,96].
The following studies with olaparib and other PARP inhibitors as
monotherapy have been largely (although not uniformly) promising,
especially in the ovarian cancer setting [18,97]. These ﬁndings have
spurred the progression into phase III development, whose results are
eagerly awaited.
3.3. Is a synthetic lethal approach possible in cancers with sporadic HR
deﬁciency?
The use of monotherapy with PARP inhibitors was extended to
sporadic tumors with suspected HR dysfunction, including HGSOC and
TNBC. Gelmon et al. documented for the ﬁrst time the clinical efﬁcacy
of olaparib in sporadic HGSOC patients. However, the same study
reported an unpredicted failure in the breast cancer setting, casting a
shadow that would subsequently put into question the actual effective-
ness of PARP-targeted therapeutics in sporadic TNBC [18]. The road
toward an effective use of PARP inhibitors in TNBC has been complicated
by misleading trials with iniparib, a proposed non-competitive agent
that raised high optimism in a phase II clinical trial [98]. The startling
failure of the subsequent phase III study [99] and the retraction of
iniparib due to lack of PARP inhibitory activity [100] depressed further
advances and underscored the need for more accurate trial designs. It
is conceivable that deeper mechanistic insights into TNBC may put
forward novel therapeutic strategies to maximize the efﬁcacy of PARP
inhibitors.
More encouraging data have emerged in the ovarian cancer setting,
where niraparib (previously MK-4287, with in vitro IC50 of 3.8 nM and
2.1 nM for PARP1 and PARP2, respectively, and less than 330-fold
potency against PARP3, PARP4 and TNKS [93]) showed signiﬁcant
antitumor activity [97], andmaintenance therapy with olaparib consid-
erably improved progression free survival in patients with platinum-
sensitive HGSOC [101]. The less compelling efﬁcacy of PARP inhibitors
in sporadic breast cancer as compared with the ovarian setting could
reﬂect either inherent setbacks imposed by the high heterogeneity of
TNBC or inadequate trial design, suffering from small sample size and
lack of biomarker-driven inclusion criteria. Another explanation could
be the higher prevalence of HR defects in ovarian cancer compared to
breast cancer [75]. Outside the breast and ovarian cancer settings,
antitumor activity of PARP inhibitionwithMK-4287 is also documented
in non-small-cell lung cancer and prostate cancer, holding the promise
for further expansion of PARP-targeted strategies [97].
3.4. Combination of PARP inhibitors with targeted agents
A step forward in the landscape of PARP inhibitors involves the
rational combination with targeted agents known to derange HR,
which is expected to induce BRCAness. A striking example has been
provided by inhibition of cyclin-dependent kinase 1 (CDK1), a core-
component of the cell cycle apparatus that is also involved in BRCA
activity [102]. CDK1-mediated phosphorylation of BRCA is required forthe formation of repair foci at the sites of DNA damage. Consistently,
neutralization of CDK1 impairs BRCA function both in vitro and in vivo,
thus mirroring BRCA-deﬁciency and imparting susceptibility to PARP
inhibition [102]. These preclinical data have encouraged the initiation
of a phase I clinical trial testing the combination of the PARP inhibitor
veliparib (formerly ABT-888, a very selective inhibitor with in vitro
IC50 of 8.3 nM and 11 nM toward PARP1 and PARP2, and 1000-fold
less activity against TNKS [93]) with the CDK inhibitor dinaciclib in
patients with advanced solid tumors (NCT01434316). This trial is
ongoing, and results are not yet available.
Another opportunity to bring about BRCAness stems from the PI3K
pathway, which is commonly activated in a wide array of tumors.
PI3K inhibition has been reported to decrease the expression of BRCA1
and BRCA2, thereby disabling HR-mediated repair and sensitizing
BRCA wild-type TNBC cells and xenografts to PARP inhibition [103].
Mechanistically, PI3K inhibitors stimulate ERK-mediated activation of
ETS transcription factors, which in turn negatively control BRCA expres-
sion [103]. Based on these ﬁndings, a phase I clinical trial is currently
underway to evaluate concurrent PARP/PI3K inhibition in TNBC and
HGSOC patients (NCT01623349).
ETS transcription factors are more generally hyperactivated in many
tumor types, including prostate cancer, Ewing's sarcoma, breast cancer,
and melanoma [104]. In a substantial percentage of prostate tumors
(50%), ETS overexpression due to genomic rearrangements increases
the formation of DNADSBs through reduced BRCA expression; therefore,
PARP blockade has been successfully applied to exacerbate the DNA
damage phenotype and kill ETS fusion-positive cells in preclinical
models [104]. At present, a phase II study with olaparib has been
approved in castration-resistant prostate cancers, also including the
assessment of ETS fusion frequency and association with response
rates (NCT01972217).
Combinatorial strategies with PARP and other targeted agents also in-
clude inhibitors of HSP90 or histone deacetylases, which are expected to
reduce the expression of HR-related proteins by mechanisms involving
proteasomal degradation and transcriptional regulation, respectively [57].
Tyrosine kinases have been reported to interfere with DNA damage
repair to support tumor development. One example is c-ABL, known
to increase RAD51 levels and promote drug resistance. In preclinical
models, targeting c-ABL by imatinib mesylate enhances radiosensitivity
and chemosensitivity of cancer cells [105], suggesting that combining
clinically applicable c-ABL inhibitors with PARP inhibitors may prove
beneﬁcial. EGFR is positively implicated in both HR (by regulating
BRCA1 function) and NHEJ dynamics (through binding with DNA-PK)
[106,107]; accordingly, in a variety of preclinical models, inhibition of
constitutively active EGFR hampers DNA repair and enhances
susceptibility to PARP obstruction [108–110]. In the clinic, combina-
tion therapy with olaparib and EGFR inhibitors is being currently
evaluated in phase I and phase II studies in patients with head and
neck cancer (NCT01758731) and EGFR-mutant non-small cell lung
cancer (NCT01513174), respectively.
A striking synthetic lethality relationship was recently evidenced
between PARP and HER2 inhibition in HER2-overexpressing breast
cancer cells. In this setting, the efﬁcacy of PARP inhibitors was not
ascribed to disturbance of DNA repair but rather to interception of the
NF-κB pathway, which critically contributes to the growth and survival
of HER2-overexpressing mammary tumors [111].
Aberrant activation of c-MYC is associated with resistance to DNA
damaging agents. Very recently, a key role for this master oncogene in
promoting PARP-dependent DNA repair has been uncovered, possibly
explaining the chemoresistant phenotype of MYC-overexpressing
cells. Basically, c-MYC liberates PARP1 from the inhibitory interaction
with the adaptor protein BIN,which enhancesDNA repair and resistance.
Therefore, PARP inhibitors could be employed to sensitize MYC-driven
tumors to DNA damaging agents [112].
Finally, hypoxia is known to impinge on DNA repair pathways by
decreasing the expression and activity of HR-related proteins. Therefore,
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tion as a consequence of the so called “contextual synthetic lethality”
[113]. As hypoxic subregions due to uneven blood supply are present
in solid tumors, PARP inhibitors could be more widely used in combina-
tion with anti-angiogenesis strategies to enhance selective cell killing. A
phase I study has been conducted in which PARP blockade by olaparib
was combinedwith VEGFR inhibition by cediranib in ovarian and breast
cancer patients, documenting encouraging activity in the ovarian
setting, despite signiﬁcant hematologic toxicity [114]. Instead, the
combination of olaparib with the anti-VEGF monoclonal antibody
bevacizumab is well-tolerated and awaits phase II studies to assess
the clinical efﬁcacy of this contextual synthetic lethal approach
[115]. In parallel, other PARP inhibitors are under phase I clinical
evaluation with bevacizumab and chemotherapy in various tumor
types (NCT01459380; NCT00989651).
4. Mechanisms of resistance to PARP blockade
4.1. Resistance to PARP inhibitors: a common roadblock
The success of cancer targeted therapies is counteracted by the
emergence of multiple resistance mechanisms, involving integrated
cell autonomous and non-autonomous routes that compensate for the
drug-induced neutralization of individual signaling pathways. This
issue has been traditionally investigated with regard to targeted agents
against catalytically hyperactive oncoproteins [116], but instances
of drug tolerance have also been documented in the context of non-
oncogene addiction. There is now compelling evidence that the presence
of BRCA1/2 mutations per se does not vouch for durable antitumor
response in patients treated with PARP inhibitors [117]. Several mecha-
nisms leading to both intrinsic and acquired resistance to PARP inhibitors
have been discovered at the preclinical level and someof themhave been
eventually validated in cancer patients [118,119].
4.2. Recovery of BRCA function by secondary mutations
The ﬁrst experimental evidence that tumors may escape PARP
inhibitor-mediated toxicity was provided by two independent groups
in 2008, dampening the enthusiasm swelled only three years earlier
with the discovery of the PARP-BRCA synthetic lethal paradigm [120,
121]. In both studies, drug resistancewas linked to secondarymutations
that restore the open reading frame and the original function of BRCA2,
thereby reinstating HR competence. Different from common oncogene-
related resistancemechanisms, wherebymissense genetic lesions occur
within the drug target that preclude compound binding, refractoriness
to PARP inhibitors arises from genetic deletions in the synthetic lethal
partner (BRCA2) that disarm BRCA/PARP functional dependency.
Selective drug pressure is likely to foster the emergence of pre-existing
resistant clones in a Darwinian fashion. In keeping with this notion
and akin to accredited escape routes to tailored therapies, data from a
single unresponsive patient unveiled the presence of secondary BRCA1
mutation in rare cells of pre-treatment material from the matched
tumor [122]. It has been proposed that resistance to PARP inhibitors
may be paradoxically promoted by the very same DNA repair defects
(and the ensuing genome instability) that drive initial PARP inhibitor
sensitivity [123].
In the future, it will be crucial to identify novel therapeutic avenues
to overcome restoration of BRCA1/2 proﬁciency. Some hints in this
direction have been advanced by Helleday and collaborators, who iden-
tiﬁed 6-thioguanine, a purine analog able to induce DSBs, as an effective
agent in eradicating genetically-reverted BRCA2mutant tumors resistant
to PARP inhibition [124]. However, additional strategies that selectively
halt tumors exhibiting acquired resistance to PARP inhibitors are urgently
warranted, as are further studies to deﬁnitely assess the clinical incidence
of HR-restoration through genetic reversion of BRCA1/2.4.3. Loss of 53BP1 expression
Newmechanistic insights into resistance to PARP inhibitorswerepro-
vided by two landmark studies which disclosed BRCA1/2-independent
routes to retrieved HR competency. Herein, loss of P53-binding protein
1 (53BP1), a protein implicated in DNA repair response, was reported
to rescue HR proﬁciency in BRCA1-mutated cells, thus installing cell
tolerance to both DNA-damaging agents and PARP inhibition [125,126].
Mechanistically, 53BP1prevents resection of ssDNA,which is preparatory
for the ensuing recombination events, as speciﬁed in 2.1; therefore, loss
of 53BP1 unleashes DNA end-resection and HR competency, proving
“synthetically viable”with BRCA1 deﬁciency [127].
53BP1 expression is reduced in a signiﬁcant fraction of triple-
negative and BRCA1/2-associated breast cancers, possibly accounting
for therapy unresponsiveness [126]. Decreased 53BP1 levels have also
been detected in BRCA1-mutant ovarian carcinoma patients that devel-
oped secondary resistance to PARP inhibitors and platinum compounds
[128]. However, it should be noted that there is no objective consensus
as to how 53BP1 loss impacts tumor response in the clinical setting:
53BP1 expression was shown neither to unequivocally correlate with
BRCA1 status nor to segregate with resistance to platinum therapy, as
it would have been expected frompreviousﬁndings [129]. Hence, larger
studies are needed to determinewhether 53BP1 expressionmaypredict
DNA repair status in biomarker-driven clinical trials.
4.4. Residual activity of mutant BRCA
The notion that secondarymutation of BRCA1may elicit tolerance to
genotoxic agents or PARP inhibitors was complemented by the ﬁnding
that discrete BRCA1mutations can differently impinge ondrug response.
In particular, the C61G mutation within the N-terminal RING domain
of BRCA1 yields a mutant BRCA1 protein still retaining partial biological
activity, which sufﬁces for reduced drug sensitivity [130]. Residual
BRCA1 activity may also result from HSP90-mediated stabilization of a
BRCA1 variant with a mutation in the BRCT domain that impairs protein
folding but does not completely prevent protein activity. In this case,
HSP90 is engaged under PARP inhibitor selective pressure to prevent
protease-mediated degradation of the misfolded hypomorphic BRCA1,
resulting in functional recovery of HR [128]. Overall, this evidence
advises the opportunity to incorporate testing of individual BRCA1
mutations into biomarker-driven clinical trials.
4.5. Upregulation of efﬂux transporters
Overexpression of ATP-binding cassette transporters (ABC), such as
P-glycoprotein (P-gp) and ABCG2, is universally recognized to mediate
drug exclusion and therapy failure [131]. Several lines of evidence indi-
cate that drug efﬂux-based resistance occurs also for PARP inhibitors;
notably, this mechanism can be reversed by administration of P-gp
inhibitors [132,133].
Mechanistically, a number of possible explanations as to how PARP
obstruction enhances efﬂux pump expression have been proposed.
P53 is known to negatively regulate P-gp expression and is frequently
defective in PARP-deﬁcient cells; hence, lack of functional P53 response
may account for resistance [132]. Another hypothesis calls attention to
the well-established role of PARP1 in transcriptional regulation and
chromatin remodeling. Although there is no direct experimental evidence
that PARP1 is able to bind the P-gp promoter to repress transcription,
such a regulatory complex might actually be operative in cells and
therefore liable to PARP inhibitor-mediated disengagement; this would
ultimately unleash P-gp expression and convey drug resistance [134].
Given the relatively recent development of clinical studies, there is
little knowledge as towhether and how frequently P-gp overexpression
occurs in patients; nevertheless, data gathered so far surmise a likely
therapeutic applicability. Hints for circumventing this resistance
machinery have also been proposed. For example, either administration
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obstruction have already been productively implemented at the pre-
clinical level and hold promise for prospective extrapolation to the
clinical setting [133,135].
4.6. Aberrant PARP expression and activity
Inactivation of PARP by reduced protein expression appears to exert
different (if not opposite) effects compared with catalytic inactivation
by pharmacologic inhibition [119]. Indeed, initial evidence suggests
that low PARP levels (and activity) attenuate responsiveness to PARP
inhibitors [90]. In hindsight, this apparent discrepancy is sound:
decreased PARPproteinmight be selectively advantageous towithstand
the “poisoning” activity of drug-induced DNA-PARP aggregates [50].
This hypothesis is in agreement with results from insertional mutagen-
esis screens that identify PARP1-depleted cells as up to 100-fold more
resistant to olaparib as compared with wild type cells [136]. Therefore,
PARP1-depleted cells may experience loss of cell viability (through
SSB repair inhibition) but also resistance to PARP inhibition (through
preclusion of PARP-trapping cytotoxic effect).
5. Predictive biomarkers of sensitivity to PARP inhibitors
5.1. Array-based procedures: “BRCAness” signatures
Validation of predictive biomarkers for PARP-directed therapeutics
is a major task and a difﬁcult endeavor. Genetic testing for BRCA1/2
mutations is being increasingly integrated in the clinical management
of patients diagnosed with breast and ovarian cancer. However, this
criterion may underestimate the real fraction of patient with BRCA-like
tumors likely to beneﬁt from PARP inhibition. For instance, epigenetic
silencing of BRCA1/2 would not be detected, thereby excluding a consis-
tent population of responding patients.
The need to tackle overall dysfunctional HR for broadening the
therapeutic span of PARP inhibitors – independently of BRCA1/2 –
brings with it the inherent hurdle to identify predictive biomarkers for
patient selection through readily applicable procedures. Targeted
genotyping assays, even when using custom panels, may reveal inade-
quate due to the high number of genes involved in DNA repair response
and the heterogeneous nature of their genetic/epigenetic inactivation.
Therefore, array-based strategies, including gene expression proﬁling,
comparative genomic hybridization, and quantitative copy number
analysis by multiplex ligation-dependent probe ampliﬁcation, have
been implemented to build BRCA1/2-like classiﬁers for the generation
of “BRCAness” signatures [137–139].
In a complementary perspective, BRCAness proﬁling by proteomic
approaches pinpointed molecular patterns of HR deﬁciency and proved
to positively associate with response rate and disease recurrence, thus
showing good predictive value [140,141]. An alternative avenue was
recently proposed by Abkevich and colleagues, who successfully devel-
oped an “HRD score” (homologous recombination deﬁciency score) for
detection and quantiﬁcation of homologous recombination defects by a
DNA-based assay [142]. Overall, these procedures may expedite a more
accurate appraisal of BRCAness and could be integrated in clinical trials.
However, a major liability is the lack of univocal correlation between a
given genetic footprint and response to therapy [130]. Indeed, individual
genetic lesions have been shown to differently impact drug response
phenotypes despite their converging onto identical genetic proﬁles.
This hints that functional rather than molecular assessment of HR proﬁ-
ciency might be more valuable for patient stratiﬁcation [130].
5.2. Functional assays to classify HRR-proﬁcient and -defective tumors
The evaluation of HR function through surrogate biomarkers directly
in patient biopsies is nowdeployed in clinical trials. The focal accumula-
tion of RAD51 at the DNA lesion is a widely recognized indicator of HRintegrity; consequently, absence of RAD51 nuclear foci following
DNA damage is a functional biomarker of HR dysfunction [57].
Immunoﬂuorescence-based detection of RAD51 foci, coupled with
quantiﬁcation of additional DNA repair-related proteins, has been
successfully applied to classify tumors as either HR-competent
(RAD51 foci-positive) or HR-defective (RAD51 foci-negative), with
a strong predictive value for chemotherapy response [143–145]. A
possible drawback of this method is that RAD51 expression is cell
cycle-dependent, which increases the likelihood of incurring in
false-negative outcomes. It should also be noted that a retained ability
to form RAD51-containing foci does not universally segregate with HR
competence. Hence, this criterion could erroneously exclude tumors
still amenable to PARP inhibition [146]. Another key protein involved in
DNA repair is histone H2AX, which also assembles as foci at DNA DSBs
in the setting of HR-competence, where it becomes phosphorylated
(gamma-H2AX) to attract additional effectors. Therefore, the degree
of gamma-H2AX foci is widely employed to assess the extent of DNA
damage in patients [147].
An inherent limitation of these procedures is the need for fresh
tissues, whose availability is not always predictable. Circulating tumor
cells (CTCs) in the peripheral bloodof patients are permanently accessible
and, in principle, would allow for non-invasive response monitoring and
biomarker discovery research in longitudinal studies [148]. Therefore,
studies are underway to score gamma-H2AX and RAD51 foci through
CTC isolation and processing [149].
Finally, it is increasingly evident that high PARP activity identiﬁes
HR-defective cells [150], possibly as a compensatory feedback. A
surrogate for PARP activity, which is leveraged for dose selection
during the development of PARP inhibitors, is detection of PARpolymers.
Therefore high PAR levels, as assessed by PAR polymers, may classify
BRCA-like tumors [151].
6. Beyond Dna repair
6.1. Targeting angiogenesis and metastasis with PARP inhibitors
The extremeversatility of the PARP family highlights the existence of
DNA repair-independent functions that may be targeted for cancer
treatment. Although long underrated, these mechanisms include
transcriptional regulation, mitotic functions, and interference with
oncogenic signaling pathways [4].
PARP1 regulates transcription through mechanisms as diverse as
relaxation of chromatin structure, direct regulation of transcription
factors, association to enhancer- and/or promoter-binding complexes,
and modulation of DNA methylation [152]. Furthermore, other PARPs
(including PARP2, PARP9/ARTD9, and PARP14/ARTD8) have been
reported to modulate transcription-factor complexes [153]. Therefore,
blocking PARPs offers a unique opportunity to tackle the aberrant
activity of transcription factors in cancer [154]. The clinical relevance
of this notion is obvious, as transcription factors promote cancer
progression, including proliferation, angiogenesis and metastasis, but
have proven as yet hostile to pharmacologic targeting.
Numerous studies suggest that PARP1 inhibition impairs angiogenesis
both in vitro and in mouse models [155–157]. Speciﬁcally, PARP inhibi-
tion is reported to abolish vessel formation and endothelial cellmigration
in response to VEGF. This activity has not received full mechanistic
elucidation, but at least partially it can be ascribed to the impairment
of PARP-mediated transcription of pro-angiogenic cues such as
syndecan-4 and Id-1 [158]. Preclinically, PARP1 down-regulation
reduces angiogenic sprouts and decreases aggressiveness in xenografts
of melanoma cells [159].
PARP1 also controls (at both transcriptional and translational levels)
the expression of molecules involved in the epithelial–mesenchymal
transition, such as vimentin and Snail1 [160,161]; interception of this
activity, coupledwith the anti-angiogenic effects described above, likely
accounts for the anti-metastatic outcome of PARP inhibition in a mouse
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positive prostate cancer cell invasion, intravasation and metastasis by
disrupting ETS-mediated transcription of metastasis-related genes,
such as EZH2 [104].
Recent ﬁndings indicate that PARP1 positively regulates the activity
of key components of hypoxic adaptation and of the inﬂammatory
response, namely HIF1-α and NF-κB, respectively [162]; as a conse-
quence, PARP inhibition reduces HIF-1α- and/or NF-κB-driven tumor
proliferation, angiogenesis and metastatic ability in several preclinical
models [4,111]. Beyond PARP1, othermembers of the PARP superfamily
have been reported to affect NF-κB signaling. As an example, the
mono(ADP)-ribose polymerase PARP10 (ARTD10) inhibits NF-κB
nuclear translocation and transcriptional outcome in response to
interleukin-1β and tumor necrosis factor-α [163]. These ﬁndings unveil
a novel scenario that entails the possibility to interfere with microenvi-
ronmental capabilities, pointing to non-obvious aspects of PARP inhibi-
tion that are very far from HR-based vulnerabilities.
6.2. Additional roles of PARPs
As brieﬂy outlined above (see Section 6.1), one major non-repair
function of PARP1 is transcriptional regulation. In particular, PARP1-
mediatedmodiﬁcation of histones in response to environmental stimuli
unties the chromatin architecture, thereby allowing transcription [3].
Not mutually exclusive, PARP1 contribution to transcriptional events
also entails functional interaction with the RNA polymerase II-related
apparatus as well as with a large number of transcription factors
(including NF-κB, Elk1, Oct-1, Sox2, nuclear receptors, and others),
triggering either stimulatory or inhibitory effects [152]. PARP1 is
also reported to act as an exchange factor by assisting the release of
inhibitory molecules and the subsequent engagement of stimulatory
elements to transcriptional complexes. Neuronal differentiation provides
a paradigmatic example of thismode of action,whereby PARP1-modiﬁed
corepressors dissociate from the promoter region while speciﬁc
coactivators are recruited to elicit a neurogenic program [164].
Moreover, PARP is documented to enhance muscle-speciﬁc gene
transcription, further strengthening the emerging notion of a
context-speciﬁc (or lineage-dependent) role [165]. In this context,
PARP1 may also exert functions irrespective of its catalytic activity.
For instance, it individually acts as a scaffold to allow functional
cooperation among several regulatory molecules at the promoter
sites, including the p300/CBP acetyltransferase [166]. Increasing
attention is being placed onto additional epigenetic functions of
PARP1, including inhibition of the DNA methyltransferase Dnmt1,
cooperation with the methylcytosine dioxygenase Tet2, and interaction
with the transcriptional insulator protein CTCF [152].
Beyond PARP nuclear activities, interphase cytosolic functions are
starting to emerge, which encompass relieve of microRNA-mediated
translational repression and assembly of the so-called stress granules —
i.e., macromolecular structures embedding RNA-binding proteins that
control mRNA translation and stability upon stress conditions. This
attests to PARP involvement (in particular PARP12/ARTD12, PARP13/
ARTD13, TNKS, and PARP15/ARTD7) in cytosolic post-transcriptional
gene regulation [167].
It is important to emphasize that PARP activity is strictly NAD+-
dependent. NAD+ is a key cofactor for redox reactions (central to cellular
energetics and metabolism) as well as for non-redox events, including
signaling pathways and gene regulation [168]. NAD+ cellular availability
is warranted by both de novo synthesis (from tryptophan) and three
individual salvage pathways (involving nicotinic acid, nicotinamide,
and nicotinamide riboside), which collectively titer the cellular levels
of NAD+ and therefore inﬂuence the reciprocal activity of PARPs and
that of other NAD+-dependent enzymes [168,169]. Unwarranted
PARP1 activation due to extensive DNA damage dramatically depletes
NAD+ cellular supplies and triggers NAD+ resynthesis through the
salvage pathway. This process results in exhaustive ATP consumptionand diverts cells from apoptosis to necrotic cell death, supporting the
use of PARP inhibitors to mitigate oxidative damage during pathologic
conditions such as inﬂammatory diseases and reperfusion injury [169].
In a context-dependent manner, another mode of cell death can be
triggered, which is referred to as “parthanatos” (PARP1-dependent cell
death): in this case, PARP1 hyper-activation and the subsequent
depletion of NAD+ induce the nuclear translocation of AIP (apoptosis-
inducing factor) from mithocondria, ultimately leading to caspase-
independent cell death [170].
An additional non-repair function of PARPs relates to safeguarding of
themitotic ﬁdelity checkpoint by localizing to centrosomes, where they
catalyze the poly(ADP)-ribosylation of centrosomal proteins [171,172],
and by interacting with the tumor suppressor protein CHFR [173]. The
mitotic checkpoint enables accurate chromosome segregation during
cell division by arresting the cell cycle in case of faulty chromosome
attachment to the microtubule-based mitotic spindle. Disabling this
machinery leads to chromosome instability and aneuploidy, a gross
form of genetic instability that (similar to DNA repair deﬁciencies)
sustains tumorigenesis while representing an intrinsic weakness of
the cancer phenotype [174]. In this perspective, PARP inhibitors have
been proposed in combinatorial regimens to selectively kill cancer
cells resistant to microtubule-stabilizing agents [173].
Novel lines of investigations may help maximize the efﬁcacy of
PARP-related approaches. Recent preclinical data have emphasized the
link between PARP inactivation and the induction of a senescent pheno-
type [175]. This could be particularly relevant in the advanced tumor
setting, where key effectors of therapy-induced senescence are likely
to be inactivated, resulting in drug resistance [176]. Hence, PARP
targeting holds promise as a pro-senescence therapy against cancer.
Novel prospects may also stem from the recent ﬁnding that PARP
inhibition-driven senescence is associated with the secretion of immu-
noregulatory molecules by senescent cells, resulting in a strong anti-
tumor immune response [177]. The notion of a “senescence-associated
secretory phenotype” is now emerging as a response to sustained DNA
damage, which involves communication with the microenvironment
and could be therapeutically exploited [178].6.3. Tankyrases 1 and 2: promising targets in anti-cancer drug development
Recent studies on other members of the PARP superfamily, namely
tankyrase 1 (TNKS) and its closest related homologue, tankyrase 2
(TNKS2), have disclosed unanticipated paths for therapeutic interven-
tion. Tankyrases 1 & 2 were originally implicated in telomere mainte-
nance through their ability to poly(ADP)-ribosylate the telomeric
repeat binding factor 1 (TRF1), a negative regulator of telomere length.
This post-translational modiﬁcation enables TRF1 disengagement from
telomeres and allows telomerase access for chromosome end elongation
(Fig. 3) [179,180]. Therefore, TNKSwas proposed as a potential target for
telomere-targeted anticancer therapy, with potential synergistic or
additive efﬁcacy with existing telomerase inhibitors [181]. The essential
drawback of telomerase-directed approaches is the lag period required
for cell senescence to occur, which could foster the emergence of
secondary resistance. Combinatorial approaches with TNKS inhibitors
are expected to integrate selective killing of cancer cells – by deﬁnition
of tumor contexts that are more reliant on telomerase activity for their
unrestrained growth –with shorter intervals needed to attain cell crisis
and senescence [181,182]. Supporting this assumption, genetic TNKS
downregulation combined with telomerase inhibition was reported to
synergistically induce telomere shortening in both gastric and lung
cancer cell lines [183,184]. Consistently, overexpression of TNKS confers
resistance to telomerase-targeted agents [181]. As mentioned in the
Introduction, these events are also modulated by PARP3, which sup-
presses telomerase activity [9]. In this perspective, broad-range PARP
inhibitors may elicit non-obvious outcomes depending on the relative
afﬁnities for either TNKS or PARP3.
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Fig. 3. Overview of Tankyrase functions.(A) Tankyrase promotes telomere elongation by PARsylating and displacing TRF1 from telomeres, thereby enabling telomerase loading onto
chromosome ends; (B) Tankyrase-mediated PARsylation of axin and ensuing axin degradation lead to disruption of the betacatenin destruction complex. Released beta-catenin
translocates into the nucleus and drives WNT-dependent transcription; (C) Tankyrase PARsylates DNA-PK, a key player in NHEJ-mediated DNA repair, and unleashes it from
proteasome-mediated degradation; (D) Tankyrase displays a multifaceted role in mitosis. First, it promotes sister chromatid resolution before anaphase (left panel); second, it forms a
complex with ATM, BRCA1 and NuMA, thereby PARsylating NuMA and ensuring spindle pole bipolarity (middle panel); ﬁnally, TNKS regulates centrosome function by interacting
with centrosome-associated proteins, such as CPAP and MIKI; (E) TNKS1/2 regulates exocytosis of GLUT4-storage vesicles upon insulin stimulation through interaction with IRAP.
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First, it forms a complex with a number of spindle-associated proteins,
includingNuMA,ATM, and BRCA1, to allowproper spindle pole focusing
and polarity [185–187]. Of note, PARP3 also enters this network by
associating to and positively regulating both NuMA and TNKS, thereby
favoringmitotic spindle integrity, telomere stability and efﬁcientmitotic
progression (Fig. 3) [8]. TNKS promotes sister telomere resolution before
anaphase: indeed, in the absence of TNKS, sister chromatids remain
associated at their telomeres due to protein–protein interactions,
which results in end-to-end fusions through the NHEJ machinery
(Fig. 3) [188–190]. It is worth noting that the TNKS sequence lacks a
nuclear localization signal, which complicates our understanding of
how TNKS can localize at telomeres both in interphase and in mitosis
[191]. A cell cycle- and TRF1-dependent distribution of TNKS has been
proposed, whereby in interphase TNKS localizes not only to telomeres
(in associationwith TRF1) but also at nuclear pore complexes; atmitosis,
when the nuclear pore complexes are disassembled, TNKS shuttles to the
pericentriolar matrix of mitotic chromosomes through a nuclear import
mechanism that is likely regulated by TRF1 [191]. This issue is currently
the object of active debate. TNKS also resides at the centrosomes and
promotes centrosome maturation by interacting with several proteins,
including the mitotic kinetics regulator, Miki, and the Centrosomal
P4.1-associated protein CPAP (Fig. 3) [192,193]. Notably, as discussed
in Section 6.2, PARPs other than TNKS are known to affect centrosome
events [171,172]. Hence, it seems that poly(ADP)-ribosylation activity,
mediated by different PARPs and affecting a diverse array of substrates,
operates as a general mechanism to assure centrosome function.
The mitotic role of TNKS implies appealing therapeutic implications.
RNA interference-mediated depletion of TNKS leads to either mitotic
arrest or senescence in several cell lines, depending on the status of
a number of negative cell-cycle regulators/tumor suppressors [10].Nevertheless, it remains unclear whether this aspect may be clinically
pursued. There is a perplexing dichotomy between TNKS genetic deple-
tion and pharmacologic blockade, in that spindle-related defects are
much feebler upon chemical inhibition as comparedwith TNKS silencing
[187]. Coherently, we also have observed that patent growth arrest, as
achieved by shRNA-mediated TNKS knockdown, is not phenocopied by
TNKS pharmacologic blockade (our unpublished results). This could
imply that residual activity in drug-treated cells may sufﬁce for rescuing
mitotic defects; alternatively, TNKS scaffolding function (disrupted by
TNKS-shRNA but spared by the drug) and catalytic activity (lost anyhow)
differently impinge on the cell mitotic apparatus. Strategies involving
TNKS inhibition in BRCA-associated cancer have been advanced to com-
bine spindle dysfunction with DNA repair defects. Indeed, a pioneering
paper documented a synthetic lethal relationship between TNKS down-
regulation and BRCA dysfunction, owing to exacerbation of BRCA1-
related mitotic defects [194].
A breakthrough in the landscape of TNKS-targeted strategy is thedis-
covery that TNKS1/2 positively modulates the canonical Wnt/β-catenin
pathway. Speciﬁcally, tankyrase-mediated poly-ADP-ribosylation of
axin, the concentration-limiting component of theβ-catenin destruction
complex, triggers axin degradation by the proteasome machinery, thus
enabling β-catenin to translocate into the nucleus and switch on the
Wnt program (Fig. 3) [195]. The Wnt signaling network is deeply in-
volved in embryonic development, stemness, cell fate determination,
neuronal migration, and cancer [196]. Genetic inactivation of APC or
oncogenic mutational activation of β-catenin yields aberrant Wnt
activation in more than 80% of colorectal cancers [197]. While this
pro-tumorigenic apparatus provides very few actionable targets for
rational drug design, TNKS may offer one such opportunity. This
assumption fueled cumulative drug development efforts to pharma-
cologically inhibit these enzymes, leading to the identiﬁcation of
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and bioavailability. Indeed, converging lines of evidence indicate
that pharmacologic TNKS blockade restrains Wnt signaling and
tumor growth in APC-mutant colorectal tumors both in vitro and
in vivo [195,198,199]. One conceivable caveat to this approach
could be a limiting intestinal toxicity [198].
Drug combination strategies may be useful to unleash the full thera-
peutic potential of TNKS inhibition. To this aim, positive hints have been
provided by studies reporting enhanced efﬁcacy of MEK- and EGFR-
directed agents in combination with TNKS inhibitors in KRAS-mutant
colorectal cancer and non-small cell lung cancer cell lines, respectively
[198,200].
TNKS1/2 play an additional role in cellular response to insulin
by regulating the plasma membrane targeting of storage vesicles
containing the glucose transporter GLUT4 and the insulin-responsive
aminopeptidase (IRAP) to facilitate glucose uptake (Fig. 3) [201].
Finally, TNKS are also involved in DNA repair by stabilizing the NHEJ
protein DNA-PK (Fig. 3) [202]. Although still in their infancy, all these
studies provide proof of concept that TNKS inhibitors could deliver ther-
apeutic beneﬁt as telomere-targeted agents and/or in the management
of Wnt-driven malignancies.
7. Concluding remarks and challenges
More than three decades have elapsed since Durkacz and colleagues
forecasted the therapeutic potential of PARP inhibitors. After years of
fortune and downfalls in the clinical arena, it is fair to say that the
impact of precisionmedicine with PARP inhibitors has been incremental
rather than transformative. Despite a sustained trend toward better
responses in BRCA-mutant patients, it is increasingly evident that BRCA
mutations as such prove neither necessary nor sufﬁcient to convey drug
sensitivity [18]. Therefore, the identiﬁcation of molecular determinants
of drug response other than BRCA still remains a major challenge.
The implementation of high-throughput functional genomics,
including large-scale siRNA sensitization screens, has led to the iden-
tiﬁcation of potentially actionable synthetic lethal candidates [203].
However, the clinical relevance of such an approach is not obvious.
One major hurdle is that artiﬁcial down-regulation of individual
genes in immortalized cell lines does not recapitulate the genetic
framework and molecular rewiring that may develop in germline
null genotypes. Moreover, genetic downregulation does not always
result in the same biological outcome as pharmacologic inhibition,
thus raising the possibility that siRNA-based investigation may
neglect (or overestimate) pursuable targets.
Integrativemolecular and functional characterization of tumorsmay
expedite the identiﬁcation of BRCA-like behaviors. In this respect,
BRCAness signatures and classiﬁers are intriguing, although they will
require prospective large-scale clinical validation before entering con-
ventional clinical practice. As a methodological caveat, the lack of gold
standards to detect BRCAness still remains an unmet challenge, which
currently precludes cross-study evaluation.
The inconclusive clinical experience with non-hereditary TNBC
suggests that the most favorable application of PARP inhibitors
should be expected in less heterogeneous (or better proﬁled) tumors
and underlines the need to reﬁne biomarker-driven clinical trials so
as to enrich for potential responders and avoid the dilution of favorable
outcomes. Efforts will be also needed to identify therapeutic restraints
to secondary resistance. Assessment of multiple biopsies or circulating
cancer cells at different time points, including at the emergence of resis-
tance, may help advance this ﬁeld. Besides, a key contingency for the
optimization of PARP inhibitors will be to analyze the consequences
of single-agent versus combination strategies, as well as intermittent
versus continuous treatment schedules.
A step forward in our knowledge about themanifold biology of PARP
and relative clinical extrapolation might derive from understanding
whether (andhowproductively)more selective compounds canovertakethe broad-spectrum PARP neutralization currently achieved with the
majority of available competitive inhibitors. Such information would
allow a more accurate interpretation of both basic research studies and
clinical trial outcomes. Indeed, olaparib targets several members of the
PARP family and also displays off-target effects (including Akt and ERK
kinases, likely contributing to antitumor activity to someextent),whereas
the highly selective inhibitor veliparib does not display any recognized
PARP-unrelated effects [204]. At present, however, studies are as yet
immature to draw a solid comparison of the consequences of pan-
PARP versus selective PARP targeting. Conversely, the road to selective
tankyrase inhibition appearsmorepracticable due to the lower homology
between tankyrases and other PARPs (with the exception of the shared
catalytic domain), although considerable skepticisms exists as towhether
TNKS1 versus TNKS2 selectivity may be attainable [93].
Another issue is to ascertainwhether theDNA-damaging insults pro-
duced by prior chemotherapy-based regimens may impact prospective
treatments by aggravating tumor heterogeneity, which would boost
the appearance of resistant clones. PARP inhibitors and chemotherapeu-
tics share a number of overlapping resistancemechanisms [94,121], but
this notion does not apply universally [97,205]. The idiosyncratic nature
of DNA repair mechanisms (and of their faulty counterparts) adds
further complexity to an already intricatematter andwill likely disorient
both the interpretation of trial outcomes and the deﬁnition of eligibility
criteria. Additional burdensmaybe imposedby the notion that biomarker
expression and prognostic value are context-dependent and may have
different relevance in different tumor types (as epitomized by the
different extent of response in sporadic BRCA-like breast and ovarian
cancers).
Despite intense research efforts, progress toward regulatory approval
of PARP inhibitors is stalling. New functional settings are emerging in
which PARP inhibitors might be therapeutically relevant — including
tumor-promoting inﬂammation, cell senescence, angiogenesis, and
metastasis. New inhibitors are being developed against more recent
members of the PARP family, such as tankyrases, which have provided
fresh knowledge on additional facets of PARP-mediated tumor biology.
We are eager to see whether and how further advances in this ﬁeld
will impact treatment decisions.
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